Minerva Neurosciences, Inc. – NASDAQ:NERV

Add to watchlist

$2.3

+0.04

+1.77%

Market closed

Open in 1 day

-33.33%

month

-33.33%

quarter

-65.23%

year

Market Cap	15.07M
Enterprise value	N/A

P/E	-0.39
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	-0.61
PEG ratio	-0.01
EPS	-4.47

Revenue	N/A
EBITDA	-24.42M
Income	-31.60M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Minerva Neurosciences, Inc. (NASDAQ:NERV): Profit margin
Jun 2023	0	-6.19M
Sep 2023	0	-7.82M
Dec 2023	0	-9.02M
Mar 2024	0	-8.56M

Minerva Neurosciences Financials Estimate

Q Y

Minerva Neurosciences, Inc. (NASDAQ:NERV): Analyst Estimates
Dec 2023	0	-9.02M
Mar 2024	0	-8.56M
Oct 2025	0	-5.75M
Dec 2025	0	-6.96M

Analysts Price target
Financials & Ratios estimates

Minerva Neurosciences, Inc. (NASDAQ:NERV): Debt to assets
Jun 2023	67138665	79.64M	118.63%
Sep 2023	63130236	83.17M	131.75%
Dec 2023	56900612	85.35M	150.01%
Mar 2024	50510415	87.09M	172.44%

Minerva Neurosciences, Inc. (NASDAQ:NERV): Cash Flow
Jun 2023	-3.87M	19.69M
Sep 2023	-6.90M	-86.69K
Dec 2023	-5.99M	19.58B
Mar 2024	-6.09M	0

Minerva Neurosciences alternative data

Minerva Neurosciences
Employees

Minerva Neurosciences, Inc. (NASDAQ:NERV): Employee count
Aug 2023	9
Sep 2023	9
Oct 2023	9
Nov 2023	9
Dec 2023	9
Jan 2024	9
Feb 2024	9
Mar 2024	9
Apr 2024	9
May 2024	9
Jun 2024	9
Jul 2024	9

Minerva Neurosciences
Hedge Funds Holdings Q1 2023

26.65% -5.74%

of NERV is owned by hedge funds

8 -9

hedge funds hold NERV stock

1.42M -306.38K

shares is hold by hedge funds

NERV hedge funds holdings changes

Minerva Neurosciences
Insider Trading

Minerva Neurosciences, Inc. (NASDAQ:NERV): Insider trades (number of shares)
Period	Buy	Sel
May 2023	0	53056

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	2 May 2023	LUTHRINGER REMY director, officer..	Common Stock	3,641	$3.76	$13,690
Sale	1 May 2023	LUTHRINGER REMY director, officer..	Common Stock	23,753	$3.85	$91,449
Sale	1 May 2023	RACE GEOFF officer: President officer: President	Common Stock	22,082	$3.85	$85,016
Sale	1 May 2023	AHLHOLM FREDERICK W officer: SVP, CFO and Secretary officer: SVP, CFO and Secretary	Common Stock	3,580	$4.48	$16,038
Sale	1 Dec 2021	KUPFER DAVID director director	Common Stock	55,635	$0.88	$48,959
Sale	16 Dec 2020	AHLHOLM FREDERICK W officer: SVP, Chief Accounting Officer officer: SVP, Chief Accounting ..	Common Stock	1,845	N/A	N/A
Sale	16 Dec 2020	REILLY JOSEPH H. officer: SVP & Chief Operating Officer officer: SVP & Chief Operating ..	Common Stock	3,228	N/A	N/A
Sale	16 Dec 2020	RACE GEOFF officer: EVP, CFO & CBO officer: EVP, CFO & CBO	Common Stock	6,190	N/A	N/A
Sale	16 Dec 2020	LUTHRINGER REMY director, officer..	Common Stock	1,300	N/A	N/A
Option	14 Dec 2020	AHLHOLM FREDERICK W officer: SVP, Chief Accounting Officer officer: SVP, Chief Accounting ..	Restricted Stock Unit	5,000	N/A	N/A

NERV insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SCHIZOPHRENIA Filling date: 16 May 2022 Issue date: 1 Sep 2022	16 May 2022	1 Sep 2022
Application	Application USE OF ROLUPERIDONE TO TREAT NEGATIVE SYMPTOMS AND DISORDERS, INCREASE NEUROPLASTICITY, AND PROMOTE NEUROPROTECTION Filling date: 2 Jul 2021 Issue date: 31 Mar 2022	2 Jul 2021	31 Mar 2022
Grant	Grant Utility: Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection Filling date: 21 Aug 2019 Issue date: 10 Aug 2021	21 Aug 2019	10 Aug 2021
Application	Application COMPOSITIONS AND METHODS FOR TREATING SCHIZOPHRENIA Filling date: 11 Sep 2020 Issue date: 29 Jul 2021	11 Sep 2020	29 Jul 2021
Application	Application METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SIGMA RECEPTOR MEDIATED DISORDERS Filling date: 29 Jun 2020 Issue date: 15 Apr 2021	29 Jun 2020	15 Apr 2021
Grant	Grant Utility: Compositions and methods for treating schizophrenia Filling date: 1 Mar 2019 Issue date: 13 Oct 2020	1 Mar 2019	13 Oct 2020
Application	Application METHODS OF USE OF PHENOXYPROPYLAMINE COMPOUNDS TO TREAT DEPRESSION Filling date: 25 Mar 2020 Issue date: 16 Jul 2020	25 Mar 2020	16 Jul 2020
Application	Application METHODS OF USING A PHENOXYPROPYLAMINE COMPOUND TO TREAT PAIN Filling date: 4 Sep 2019 Issue date: 5 Mar 2020	4 Sep 2019	5 Mar 2020
Application	Application USE OF ROLUPERIDONE TO TREAT NEGATIVE SYMPTOMS AND DISORDERS, INCREASE NEUROPLASTICITY, AND PROMOTE NEUROPROTECTION Filling date: 21 Aug 2019 Issue date: 27 Feb 2020	21 Aug 2019	27 Feb 2020
Application	Application COMPOSITIONS AND METHODS FOR TREATING SCHIZOPHRENIA Filling date: 1 Mar 2019 Issue date: 23 Jan 2020	1 Mar 2019	23 Jan 2020

Minerva Neurosciences
Earnings Call Transcripts

Quarter	Transcript
Q1 2023 15 May 2023	Q1 2023 Earnings Call Transcript
Q4 2022 8 Mar 2023	Q4 2022 Earnings Call Transcript
Q3 2022 9 Nov 2022	Q3 2022 Earnings Call Transcript
Q3 2021 8 Nov 2021	Q3 2021 Earnings Call Transcript

NERV earnings call transcripts

Minerva Neurosciences
Executives

Insider	Age	Compensation
Dr. Remy Luthringer Ph.D. (1961) Executive Chairman & Chief Executive Officer	64	$850,300
Mr. Geoffrey Robin Race F.C.M.A., FCMA, M.B.A., MBA (1961) Pres	64	$644,200
Dr. Jay B. Saoud Ph.D. (1959) Consultant	66	$613,840

Minerva Neurosciences
Latest News

Tuesday, 5 November 2024
07:30	Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates	globenewswire.com
Monday, 6 May 2024
13:01	Minerva Neurosciences (NERV) Upgraded to Buy: What Does It Mean for the Stock?	Zacks Investment Research
Tuesday, 27 February 2024
08:14	US FDA declines to approve Minerva Neurosciences' schizophrenia drug	Reuters
Wednesday, 23 August 2023
04:05	Minerva Neurosciences: There's Probably Time For One More Rally	Seeking Alpha
Friday, 9 June 2023
10:57	Here's Why Minerva Neurosciences (NERV) Is a Great 'Buy the Bottom' Stock Now	Zacks Investment Research
Monday, 5 June 2023
14:11	Nasdaq ETF's First Six-week Rally Since Jan 2020: Stock Winners	Zacks Investment Research
Friday, 19 May 2023
17:34	Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst Ahead	Seeking Alpha
Thursday, 18 May 2023
13:02	What Makes Minerva Neurosciences (NERV) a New Buy Stock	Zacks Investment Research
Monday, 8 May 2023
08:30	Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023	GlobeNewsWire
Wednesday, 8 March 2023
11:31	Minerva Neurosciences, Inc. (NERV) Q4 2022 Earnings Call Transcript	Seeking Alpha
Wednesday, 1 March 2023
08:30	Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023	GlobeNewsWire
Thursday, 29 December 2022
12:02	Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA	Zacks Investment Research
Wednesday, 9 November 2022
10:02	Minerva Neurosciences, Inc. (NERV) Q3 2022 Earnings Call Transcript	Seeking Alpha
Wednesday, 2 November 2022
08:30	Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022	GlobeNewsWire
Monday, 17 October 2022
08:51	Minerva Neurosciences to request meeting with FDA about schizophrenia drug	Market Watch
Monday, 10 October 2022
11:55	TOPS, SURG: The Top 5 Short Squeeze Stocks This Week	InvestorPlace
Monday, 26 September 2022
10:48	NERV, FAZE: The Top 5 Short Squeeze Stocks This Week	InvestorPlace
Monday, 19 September 2022
11:59	NRBO, FAZE: The Top 5 Short Squeeze Stocks to Watch This Week	InvestorPlace
Wednesday, 24 August 2022
15:45	Billionaire Steven Cohen Just Made a Big Bet on Minerva Neurosciences (NERV) Stock	InvestorPlace
Tuesday, 23 August 2022
14:17	Minerva (NERV) Submits NDA for Schizophrenia Candidate, Stock Up	Zacks Investment Research
Monday, 22 August 2022
15:31	4 Hot Penny Stocks To Watch This Week	PennyStocks
Thursday, 7 April 2022
13:01	Minerva Outlines Next Steps For US Application For Schizophrenia Candidate	Benzinga
Tuesday, 1 March 2022
10:44	Minerva Neurosciences (NERV) Reports Q4 Loss, Misses Revenue Estimates	Zacks Investment Research
Monday, 8 November 2021
14:11	Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q3 2021 Results - Earnings Call Transcript	Seeking Alpha
10:00	Minerva Neurosciences (NERV) Reports Q3 Loss, Misses Revenue Estimates	Zacks Investment Research
Monday, 1 November 2021
08:30	Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8	GlobeNewsWire
Monday, 11 October 2021
08:30	Minerva Neurosciences Announces Promotion of Geoff Race to President	GlobeNewsWire
Thursday, 30 September 2021
10:32	Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations	Benzinga
08:30	Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia	GlobeNewsWire
Monday, 27 September 2021
10:03	Implied Volatility Surging for Minerva Neurosciences (NERV) Stock Options	Zacks Investment Research

Frequently Asked Questions (FAQ)

What's the price of Minerva Neurosciences stock today?

One share of Minerva Neurosciences stock can currently be purchased for approximately $2.3.
When is Minerva Neurosciences's next earnings date?

Unfortunately, Minerva Neurosciences's (NERV) next earnings date is currently unknown.
Does Minerva Neurosciences pay dividends?

No, Minerva Neurosciences does not pay dividends.
How much money does Minerva Neurosciences make?

Minerva Neurosciences has a market capitalization of 15.07M.
What is Minerva Neurosciences's stock symbol?

Minerva Neurosciences, Inc. is traded on the NASDAQ under the ticker symbol "NERV".
What is Minerva Neurosciences's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Minerva Neurosciences?

Shares of Minerva Neurosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Minerva Neurosciences's key executives?
Minerva Neurosciences's management team includes the following people:
- Dr. Remy Luthringer Ph.D. Executive Chairman & Chief Executive Officer(age: 64, pay: $850,300)
- Mr. Geoffrey Robin Race F.C.M.A., FCMA, M.B.A., MBA Pres(age: 64, pay: $644,200)
- Dr. Jay B. Saoud Ph.D. Consultant(age: 66, pay: $613,840)
How many employees does Minerva Neurosciences have?

As Jul 2024, Minerva Neurosciences employs 9 workers.
When Minerva Neurosciences went public?

Minerva Neurosciences, Inc. is publicly traded company for more then 11 years since IPO on 1 Jul 2014.
What is Minerva Neurosciences's official website?

The official website for Minerva Neurosciences is minervaneurosciences.com.
Where are Minerva Neurosciences's headquarters?

Minerva Neurosciences is headquartered at 1601 Trapelo Road, Waltham, MA.
How can i contact Minerva Neurosciences?

Minerva Neurosciences's mailing address is 1601 Trapelo Road, Waltham, MA and company can be reached via phone at +61 76007373.

Minerva Neurosciences, Inc.

minervaneurosciences.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

+61 76007373

1601 Trapelo Road
Waltham, MA 02451

CIK: 0001598646
ISIN: US6033802058
CUSIP: 603380205